慢性阻塞性肺病急性加重期患者血嗜酸性粒细胞水平与NLR、CRP、FEV1的相关性研究
摘要
关键词
全文:
PDF参考
[1]Global Initiative for Chronic Obstructive Lung Disesae.https://goldcopd.org/2023-gold-report-2/.[2].Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717[3]MacLeod M, Papi A, Contoli M, et al . Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis,treatment,prevention and disease impact. Respirology. 2021 Jun;26(6):532-551[4]Han MK, Agusti A, Calverley PM, et al . Chronic obstructive pulmonary disease phenotypes: the future of COPD.Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604. [5]Bafadhel M,Mckenna S,Terry S,et al. Acute exacerbations of chronic obstructive pulmonary disease:identification of biologic clusters and their biomarkers[J]. Am J Respir Crit Care Med,2011,184(6):662-671[6]GAO P,ZHANG J,HE X,et al. Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic ob-structive pulmonary disease[J]. PLoS One,2013,8(5):e57678.[7]Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019 Jul;74(7):1249-1256[8]Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest. 2016Aug;150(2):320-8. [9]Ruiying W, Zhaoyun, Jianying X. Clinical features and three-year prognosis of AECOPD patients with different levels of blood eosinophils. Heart Lung. 2022 Nov-Dec;56:29-39[10]PASCUAL-GONZALEZ Y,LOPEZ-SANCHEZ M,DORCA J,et al. Defining the role of neutrophil-to-lymphocyte ratio in COPD:asystematic literature review[J]. Int J Chron Obstruct Pulmon Dis,2018,13:3651-3662[11]段榆琳,王宋平. 探讨 AECOPD 患者血清 ACE2 和 NLR 水平与 CAT 评分的相关性[J]. 南京医科大学学报(自然科学版),2019,39(7):997-999[12]DUMAN D,AKSOY E,AGCA M C,et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia[J]. Int J Chron Obstruct Pulmon Dis,2015,10:2469-2478.[13]Global Initiative for Chronic Obstructive Lung Disesae. https://goldcopd.org/2022-gold-report-2/[14]Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R;ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014 Dec;44(6):1697-700. [15]郑丹蕾,王红梅,刘耘充 等. 慢性阻塞性肺疾病患者血嗜酸粒细胞分布及临床特征[J].中华结核和呼吸杂志,2021,44(3):218-224.[16]You Y, Shi GC. Blood Eosinophils and Clinical Outcome of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Respiration. 2021;100(3):228-237. doi: 10.1159/000510516. [17]薛瑾,崔亚楠,陈平等.血嗜酸粒细胞对慢性阻塞性肺疾病急性加重期激素治疗反应性和再入院的预测价值[J].中华结核和呼吸杂志,2019(06):426-431[18]郭蓉,凌敏.血清嗜酸粒细胞水平与慢性阻塞性肺疾病急性加重的临床研究[J].国际呼吸杂志,2020,40(14):1073-1077.[19]徐婷婷,宋伟伟,承璐潇 等.嗜酸性粒细胞与慢性阻塞性肺病急 性 加 重 严 重 程 度 的 关 系 [J]. 南 京 医 科 大 学 学 报 ( 自 然 科 学版),2021,41(02):203-206+211[20]杨艳珍,庞敏. 外周血嗜酸粒细胞水平与 AECOPD 临床特征及预后的相关分析[J]. 国际呼吸杂志,2020,40(23):1771-1776[21]Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load[J].Respir Res, 2017, 18(1): 88
DOI: http://dx.doi.org/10.12361/2661-3603-05-21-149975
Refbacks
- 当前没有refback。